|
Argentina Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Argentina Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Argentina .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Argentinian pharmaceutical and healthcare industry.
Competitive intelligence, Argentinian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Argentinian market.
The Argentina Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- 2013 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Argentina Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Argentinian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Argentina to test other views – a key input for successful budgeting and strategic business planning in the Argentinian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Argentinian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Argentina .
- Exploit The Latest Competitive Argentinian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Argentina .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- 2013 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Argentina Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Argentina Pharmaceuticals And Healthcare Industry SWOT |
| Argentina Political SWOT |
| Argentina Economic SWOT |
| Argentina Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Americas Pharmaceutical Business Environment Rankings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Argentina – Market Summary |
| Regulatory Regime |
| OTC Regulation |
| Recent Regulatory Developments |
| Intellectual Property (IP) Environment |
| IP Disputes |
| Table: Joint Declaration By Latin American Health Ministers, May 2006 |
| Counterfeit Pharmaceuticals |
| Pricing Regime |
| Table Argentina - Pharmaceutical Price Build-Up |
| Table: Argentina's Drug Price Freeze, 2005-2008 |
| Reimbursement Regime |
Chapter - Industry Trends And Developments |
| Epidemiology |
| Healthcare Insurance |
| Recent Healthcare Insurance Developments |
| Domestic Pharmaceutical Sector |
| Recent Developments in Domestic Pharmaceuticals Sector |
| Multinational Sector Developments |
| Vaccines Sector |
| Recent Developments in the Vaccines Sector |
| Medicinal Plants |
| Table Argentina - Imports of Medicinal Plants by Country (US$'000) |
| Research and Development (R&D) |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Argentina - Drug Market Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Argentina – Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Argentina - Economic Activity |
| Prescription Market Forecast |
| Table: Argentina - Prescription Drug Market Indicators, Historical Data and Forecasts (ARSmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Argentina – Patented Market Indicators, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: Argentina – Generics Market Indicators , Historical Data and Forecasts |
| OTC Market Forecasts |
| Table: Argentina – OTC** Market Indicators, Historical Data and Forecasts (ARSmn unless otherwise stated) |
| Pharmaceutical Trade Forecasts |
| Table Argentina – Imports of Medicines Containing Vitamins by Country (US$'000) |
| Table: Argentina - Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) |
| Medical Device Market Forecast |
| Table: Argentina – Medical Device Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Argentina – Other Health Indicators, Historical Data and Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Monitor |
| Leading Foreign Companies |
| Pfizer |
| Roche |
| Novartis |
| GlaxoSmithKline (GSK) |
| Sanofi-Aventis |
| Merck & Co |
| Boehringer Ingelheim |
| Indigenous Manufacturers |
| Laboratorios Roemmers |
| Laboratorios Bagó |
Chapter - Country Snapshot: Argentina Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education |
| Table: Life Expectancy, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Manufacturing Wages, 1995-2001 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Argentina Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Argentina remains ranked just eighth among the 10 major pharmaceutical markets surveyed in BMI‘s Q209 Business Environment Ratings. While the country’s substantial and growing population theoretically represents a strong draw for foreign companies, the government’s lax stance on bioequivalance has resulted in many multinationals choosing to close down their local production facilities. The lack of patent protection, the imposition of strict price controls, and the government’s bias towards local producers in its purchasing policies are among the most frequent complaints levelled against the country’s operating environment. Consequently, without major improvements in intellectual property (IP) and pricing rules, the larger and better-regulated markets of Brazil, Mexico and even Colombia will continue to attract the lion’s share of multinational investment in the region,
Moreover, despite double-digit growth rates experienced in 2006 and 2007, all the more important given the economic collapse just a few years earlier, in the period between 2008 and 2013, pharmaceutical market values are forecast to post a compound annual growth rate (CAGR) of just 1.10% in US dollar terms, rising from ARS15.5bn (US$4.77bn) to ARS21.91bn (US$5.04bn). The weakening peso will result in a 7.17% CAGR, although this weakness of local currency will also continue to stimulate exports - one of the already fastest-growing areas of the market. Over the next five years, exports are expected to post a CAGR of 4.80%, above that for imports, as well as substantially above the overall market.
Given the regulatory and price constraints faced by both foreign and domestic producers, local drugmakers are increasingly focusing on fast-growing emerging markets, such as Russia and Pakistan, which are also considerably more lightly regulated. To this end, in February 2009, Laboratorios Bagó finalised a joint venture (JV) with Pakistani company Ferozsons Laboratories that envisages the creation of a new biogeneric therapies plant in Pakistan. The move follows Bagó’s exports foray into Russia, Pakistan, Vietnam and a number of other developing countries. In the longer-term, however, the pressure on the Argentina’s regulator and general improvements in regulatory systems in other key Latin American markets will inevitably force tighter regulation and enforcement of bioequivalence rules in Argentina, which should allow exports to more lucrative North American and European markets.
In the meantime, despite the stronger than expected Q408 real GDP growth figure, we continue to believe that the Argentine economy is likely to suffer substantially in 2009. In fact, we have revised down our real GDP growth forecast from 0.6% to -1.0%, and also expect a 0.9% contraction in 2010, and a growth of just 1.2% in 2011. A run on the peso as a result of the government's inflationary fiscal policy is risking a shift of individuals’ and business money out of pesos and into dollars in anticipation of more inflation. This would undermine private business activity and economic growth.
|
Argentina Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |